期刊
EUROPEAN UROLOGY
卷 69, 期 5, 页码 877-882出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2015.10.020
关键词
Renal cancer; Statin; Pharmacoepidemiology; Case-control study
资金
- Novartis
- Pfizer
- MSD
- Danish Association of Pharmaceutical Manufacturers
- Astra Zeneca
- Danish Council for Independent Research [4004-00234B]
Background: Use of statins has been suggested to protect against renal cell carcinoma (RCC); however, studies have typically been underpowered, and the results are conflicting. Objective: To determine whether the use of statins is associated with a reduced risk of RCC using high-quality registry data. Design, setting, and participants: We conducted a nationwide case-control study based on all histologically verified cases of RCC in Denmark between 2002 and 2012 (n = 4606) matched 1:10 to cancer-free controls. Data on drug use, comorbidity, and educational level were obtained from Danish nationwide prescription, patient, and demographic registries. Outcome measurements and statistical analysis: Odds ratios (ORs) and 95% confidence intervals (CIs) for RCC associated with long-term use (>= 5 yr) of statins were estimated using conditional logistic regression, adjusting for potential confounders. Results and limitations: The adjusted OR for RCC associated with long-term use of statins was 1.06 (95% CI, 0.91-1.23). Analyses stratified by duration of statin use, type of statin, and patient characteristics all yielded ORs close to unity, except for a slightly increased OR for RCC associated with long-term statin use among women (OR: 1.25; 95% CI, 0.96-1.62). The main limitation of our study was lack of information on lifestyle factors, notably obesity, which may have biased the risk estimates upward. Conclusions: Our study does not support an important chemopreventive effect of long-term statin use against RCC. The marginally increased and statistically insignificant risk estimates can readily be interpreted as a null finding, considering the lack of control for obesity and other lifestyle risk factors. Patient summary: Previous studies have shown that the use of cholesterol-lowering drugs (statins) may protect against renal cancer. In a large study including all Danish renal cancers during an 11-yr period, we found no evidence of such an effect. (C) 2015 European Association of Urology. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据